ClinicalTrials.gg
RecruitingNCT03051464MORPHEUSUpdated Jun 30, 2026

Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery

A Phase 2/3 interventional study of Complete responders and Non-complete responders and Chemoradiation + EBRT Boost in Stage II Rectal Cancer, Organ Preservation and Non-operative Treatment, sponsored by Sir Mortimer B. Davis - Jewish General Hospital. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Sir Mortimer B. Davis - Jewish General Hospital · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2017; still recruiting 9 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Rectal Neoplasms with a site in Canada — 12 open to participants now, 21 under way, 6 of them phase 3. Rectal Neoplasms · Canada.

Planned enrollment
36th of 82
131 · median 95
Started
2017
with 3 others
Phase 2/3
2 of 98
1 open now
Primary completion
2028-01
later than 13 of 20 live
Registered
69th of 98
by date
Lead sponsor
5 of 98
Sir Mortimer B. Davis - Jewish General Hospital

Among the 98 studies in Rectal Neoplasms with a site in Canada, this one is the 36th largest by planned enrollment of the 82 interventional ones that give a count, is one of 4 that started in 2017, is one of 2 in phase 2/3, reaches primary completion later than 13 of the 20 other live ones, and was the 69th registered.

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

12 of the 98 studies in Rectal Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 406 Rectal Neoplasms studies recruiting now, 211 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Rectal Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

A randomized study of 131 patients. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions).

Read the detailed description

It is becoming clear that there is a now an international consensus that rectal cancer research efforts need to be more focused in optimizing a non-surgical approach. This concept is very relevant to an ageing patient population with multiple co-morbidities regularly seen at the Jewish General Hospital and across the province. After interim analysis on 40 patients of the pilot study a phase III study is proposed. We are therefore proposing a phase III multicentric study of 145 patients to compare the two best known radiation dose escalation strategies and to achieve a complete clinical response. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions). Patients that have a high risk of recurrence or with more advanced stages of the disease will be excluded from the study, as only the local disease is being treated. The primary outcome for this proposal is rectum preservation in treated patients.

03

Conditions studied

  • Stage II Rectal Cancer
  • Organ Preservation
  • Non-operative Treatment
  • Rectal Cancer (Stage III)
  • Rectal Cancer Patients

Browse trials for

Keywords

  • rectal cancer
  • non-operative management
  • rectal preservation
  • organ preservation
  • brachytherapy boost for rectal cancer
  • low rectal cancer curative treatment
  • mid rectal cancer curative treatment
  • rectal brachytherapy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Rectal cancer patients, clinically staged as T2-T3a,b N0-1 by MRI or endoscopic/trans-rectal ultrasound
  • Rectal cancer staged as N0-1 by MRI or EUS/TRUS
  • No lesion
  • Rectal tumor occupying less than half of the circumference
  • Tumor less than 5 cm on its largest dimension
  • Tumor located at less than 10 cm from the anal verge
  • Tumor penetration less than 5 mm in the mesorectal fat
  • Tumor accessible for brachytherapy
  • Lumen accessible for colonoscopy
  • Patient should be a suitable candidate for brachytherapy and chemotherapy
  • Older than 18 years of age
  • Adequate measures in women of
  • Written

Exclusion criteria

Exclusion Criteria:

  • Patients with previous pelvic radiation
  • Evidence of distant
  • Extension of malignant disease to the anal canal
  • Tumors staged as T4
  • Tumors larger than 5 cm in length
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
131 participants (estimated)

Study arms

  • Experimental
    Chemoradiation + EBRT Boost

    standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5; Complete responders and Non-complete responders

    Procedure: Complete responders and Non-complete responders · Radiation: Chemoradiation + EBRT Boost

  • Experimental
    Chemoradiation + HDRBT Boost

    standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions; Complete responders and Non-complete responders

    Procedure: Complete responders and Non-complete responders · Radiation: Chemoradiation + HDRBT Boost

Interventions

  • ProcedureComplete responders and Non-complete responders

    Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.

  • RadiationChemoradiation + EBRT Boost

    45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5

  • RadiationChemoradiation + HDRBT Boost

    45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions

06

What researchers measure

Primary outcomes

  1. TME-free survival

    Time from date of randomization to either TME or death in the intention to treat population

    Time frame: 2 years post treatment

Secondary outcomes

  1. Local Recurrence

    Number of participants with Local recurrence as assessed by tests during follow-up visits.

    Time frame: 2 years post treatment

  2. Disease-free survival

    The time between the date of randomization and recurrence, either in the pelvis or metastases. Patients without an event will be censored at the last date the patient was known to be disease-free.

    Time frame: 5 years post treatment

  3. Overall survival

    The time between date of randomization and date of death due to any causes.

    Time frame: 5 years post treatment

  4. Overall Quality of life

    Quality of life Questionnaires over different time point

    Time frame: 5 years post treatment

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2017 (actual). Primary completion is estimated for Jan 2028, 129 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2017
First posted
Feb 13, 2017
StartActual
Apr 25, 2017
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2030
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03051464
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Responsible party
Dr. Te Vuong (Director, Radiation Oncology Department, Sir Mortimer B. Davis - Jewish General Hospital) — Principal investigator
First posted
Feb 13, 2017
Start date
Apr 25, 2017
Primary completion
Jan 2028 (estimated)
Completion
Jan 2030 (estimated)
Last update
Jun 30, 2026

Study contacts

Susanne Knoepfel
Contact
sknoepfel@jgh.mcgill.ca
5143408288 ext. 21285
Te Vuong, MD
principal investigator · Sir Mortimer Jewish General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion